Dr. Sarret joined Corium as Chief Business Officer in 2015. Most recently, Dr. Sarret served as Senior Vice President, Strategic Accounts at Solazyme, Inc., a renewable oils company, and as Chief Executive Officer and a Director of Sevident, Inc., a start-up biotechnology company. Prior to joining Sevident, Dr. Sarret held positions of increasing responsibility at Codexis, Inc., an international industrial biotechnology company, including Chief Business Officer and President, Pharmaceutical Services and Enzyme Products. At Codexis, he was responsible for numerous strategic partnerships, including multi-product development and supply agreements and complex licensing transactions. In addition, Dr. Sarret had P&L responsibility for the company's global pharmaceutical ingredient manufacturing business unit. Previously, he practiced corporate and transactional law with Latham & Watkins LLP. Dr. Sarret also served as Attending Physician and Acting Medical Director for the HIV Clinic at the University of California, San Francisco Medical Center. Dr. Sarret holds a B.A. in Human Biology from Stanford University, an M.D. from the University of California, San Francisco School of Medicine and a J.D. from Stanford Law School.
Mr. Staple has more than 25 years of experience in the biotechnology and pharmaceutical industries. He previously served as Chief Executive Officer and a Director of BioSeek, Inc., a pioneer in applying predictive human biology to drug discovery, and as a member of the senior executive team at ALZA Corporation, the leader in applying drug delivery technologies to develop new therapeutics. At ALZA, as Executive Vice President, Chief Administrative Officer and General Counsel, he played a central role in partnering transactions, financings and acquisitions, as well as ALZA’s merger with Johnson & Johnson.
Prior to joining ALZA, Mr. Staple served in senior positions at Cetus and Chiron Corporations, where his responsibilities covered corporate partnering, licensing, mergers and acquisitions, and financings, including transactions involving commercialization of polymerase chain reaction, hepatitis C and HIV screening technologies. Prior to entering the biotechnology industry, Mr. Staple practiced corporate and securities law with Heller Ehrman LLP. Mr. Staple serves on the board of directors of Depomed, Inc., and has served multiple terms on the board of visitors at Stanford Law School. He holds B.A. and J.D. degrees from Stanford University.
Mr. Arsulowicz is the Vice President, Operations for Corium's Grand Rapids, Michigan site. Dan has more than 15 years of experience and management in Engineering and R&D development and operations in the pharmaceutical, medical device and OTC fields. He has led his teams through successful regulatory filings and approvals, as well as commercial scale-up of multiple transdermal, medical device and oral healthcare products. Prior to joining Corium in April 2002, Dan held R&D and operations roles at Amway Corporation; where he was responsible for process development, scale-up, continuous improvement programs and general operational support for various products. Dan received a B.S. in Chemical Engineering from the University of Michigan and an M.B.A. from Grand Valley State University.
Mr. Breuil joined Corium in September 2012. Prior to that, he had been the Chief Financial Officer of Codexis, a developer of cost-advantaged processes for the production of pharmaceuticals, bio-based chemicals, and biofuels. While at Codexis, Mr. Breuil raised over $150 million in five private equity and debt financings, and oversaw and managed the growth of that organization from less than 100 employees in two sites to 300 employees spread across five countries and three continents. Under his leadership, the company implemented global compliance with the Sarbanes-Oxley Act and filed for an initial public offering. Prior to Codexis, Mr. Breuil was the Chief Financial Officer of Aerogen, a specialty pharmaceutical company focusing on the field of aerosolized drug delivery, which was acquired by Nektar Therapeutics in October 2005. Mr. Breuil was at ALZA Corporation for seven years before Aerogen, where he held numerous positions including Director of Corporate Planning and Analysis and Controller, staying on as Controller when ALZA was acquired by Johnson & Johnson. Before his industry experience, he served for eight years as a Naval Officer and Aviator. Mr. Breuil holds a B.S. in Electrical Engineering at the United States Naval Academy and an M.B.A. from the Stanford Graduate School of Business.
Ms. Dickerson reports directly to the Chief Executive Officer, working closely with the CFO and the Vice President of R&D on business and financing matters. She has over 15 years of investment banking experience, including mergers and acquisitions, leveraged buyouts, high yield financing, arbitrage, numerous divestitures and general corporate finance. Ms. Dickerson began her career at Salomon Brothers Inc in the High Yield finance group, leaving to become the director of M&A of Great Pacific Capital, the merchant banking arm of the Jim Pattison Group, where she also managed their US portfolio of companies. Ms. Dickerson also led and executed several specific divestitures for a private family company before returning to J.P. Morgan & Co in 1999, where she managed the private banking relationships and a large investment portfolio for high net worth individuals consisting of Silicon Valley executives and venture capitalists. She has been with Corium since 2003. Ms. Dickerson has an A.B. in International Relations and an A.B. in Economics from Stanford University.
Dr. Singh is the Chief Technology Officer and Vice President, Research and Development at Corium. He has over 15 years of experience in the pharmaceutical and drug delivery industries. He has held R&D and senior management positions at Ciba-Geigy, Novartis, Vyteris and Corium. He has led the development of several novel passive and active transdermal technology platforms, which resulted in commercialization of a number of transdermal and oral healthcare products. Dr. Singh has over 40 publications in peer reviewed journals and over 25 issued and pending patents. He holds a Ph.D. in Pharmaceutics from the University of Queensland, Australia and a Post-Doctoral fellowship from the University of California at San Francisco. He is a member of the American Association of Pharmaceutical Scientists and the Controlled Release Society.
Mr. Sweemer has over 40 years of experience as a chief financial officer and working for a Big Four accounting firm. He started his career with KPMG, working with clients in various industries and with considerable experience in M&A transactions and public financings. He then transitioned into senior financial roles with several companies and in various industries, including capital equipment and custom apparel manufacturing. Prior to joining Corium, Mr. Sweemer spent 12 years as Chief Financial Officer for a high tech electronics company, which was a venture capital funded spin-off of a large international company. He holds a B.B.A. degree in Accounting from the University of Wisconsin - Whitewater, graduating Magna Cum Laude. He is a CPA and a CGMA.